This firm currently holds 383.49
M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. The company has a current ratio of 3.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Supernus Pharmaceuticals has an asset utilization ratio of 213.26 percent. This suggests that the company is making $2.13 for each dollar of assets. An increasing asset utilization means that Supernus Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
We determine the current worth of Supernus Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Supernus Pharmaceuticals based exclusively on its
fundamental and basic
technical indicators. By analyzing Supernus Pharmaceuticals's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Supernus Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Supernus Pharmaceuticals. We calculate exposure to Supernus Pharmaceuticals's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Supernus Pharmaceuticals's related companies.
Supernus Pharmaceuticals Investment Alerts
Supernus investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Supernus Pharmaceuticals performance across your portfolios.Please check all
investment alerts for Supernus
Supernus Pharmaceuticals Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Supernus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Supernus Pharmaceuticals competition to find
correlations between indicators driving the intrinsic value of Supernus.
Supernus Pharmaceuticals Gross Profit
Supernus Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Supernus Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Supernus Pharmaceuticals Gross Profit growth over the last 10 years. Please check Supernus Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Going after Supernus Financials
The latest indifference towards the small price fluctuations of Supernus Pharmaceuticals created some momentum for institutional investors as it was traded today as low as
22.16 and as high as
23.46 per share. The company management teams did not add any value to Supernus Pharmaceuticals investors in
July. However, most investors can still diversify their portfolios with Supernus Pharmaceuticals to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 2.26. The current volatility is consistent with the ongoing market swings in
July 2020 as well as with Supernus Pharmaceuticals unsystematic, company-specific events.
Margins Breakdown
Supernus profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Supernus Pharmaceuticals itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Supernus Pharmaceuticals profit margins.
| Operating Margin | 31.37 |
| EBITDA Margin | 31.67 |
| Gross Margin | 90.2 |
| Profit Margin | 25.2 |
Supernus Pharmaceuticals Net Income Per Employee is quite stable at the moment. Moreover, Supernus Pharmaceuticals Revenue Per Employee is increasing over the last 8 years.
Does Supernus Pharmaceuticals have anything more to disclose in August?
Latest Risk Adjusted Performance is up to -0.04. Price may slide again. Supernus Pharmaceuticals exhibits very low volatility with skewness of 0.12 and kurtosis of 0.71. However, we advise investors to further study Supernus Pharmaceuticals technical indicators to make sure all market info is available and is reliable.
Our Bottom Line On Supernus Pharmaceuticals
Whereas other companies in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Supernus may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take up new shares of Supernus nor sell your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Supernus Pharmaceuticals.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Supernus Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
